Related Experiment Video
Updated: Aug 26, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Racial, ethnic, and sex disparities in atrial fibrillation management: rate and rhythm control
Sofia E Gomez1, Muhammad Fazal1, Julio C Nunes2,3,4
1Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, H2146, Stanford, CA, 94305, USA.
Insights
Disparities exist in atrial fibrillation (AF) management and outcomes among women and racial/ethnic minorities. These groups face worse symptoms and less treatment despite lower AF prevalence, highlighting inequities in care and research representation.
Area of Science:
- Cardiology
- Health Disparities
- Clinical Research
Background:
- Atrial fibrillation (AF) impacts millions, requiring pharmacologic and interventional management for rate/rhythm control and stroke prevention.
- Existing AF management strategies may yield different responses across diverse populations.
- This review focuses on disparities in AF rate/rhythm control and outcomes for women and underrepresented racial/ethnic groups.
Purpose of the Study:
- To explore sex and racial/ethnic disparities in AF rate and rhythm management.
- To analyze the impact of these disparities on patient outcomes.
- To review AF epidemiology and clinical trial diversity.
Main Methods:
- Narrative review of existing literature.
- Exploration of sex and racial/ethnic disparities in AF management.
- Summary of AF epidemiology and landmark clinical trials.
Main Results:
- Black and Hispanic adults have lower AF risk but more severe symptoms and lower quality of life than NHW patients.
- NHW patients receive more frequent antiarrhythmic drugs, cardioversions, and invasive therapies.
- Women experience more severe symptoms, heart failure, stroke, and death post-AF diagnosis; underrepresentation in trials may affect prevalence data.
Conclusions:
- Social determinants like race, ethnicity, and gender influence AF prevalence, progression, and management.
- Biological differences and treatment/research disparities contribute to observed impacts.
- Addressing these disparities is crucial for equitable AF care.
Background:
Atrial fibrillation (AF) affects around 6 million Americans. AF management involves pharmacologic therapy and/or interventional procedures to control rate and rhythm, as well as anticoagulation for stroke prevention. Different populations may respond differently to distinct management strategies. This review will describe disparities in rate and rhythm control and their impact on outcomes among women and historically underrepresented racial and/or ethnic groups.
Methods:
This is a narrative review exploring the topic of sex and racial and/or ethnic disparities in rate and rhythm management of AF. We describe basic terminology, summarize AF epidemiology, discuss diversity in clinical research, and review landmark clinical trials.
Results:
Despite having higher rates of traditional AF risk factors, Black and Hispanic adults have lower risk of AF than non-Hispanic White (NHW) patients, although those with AF experience more severe symptoms and report lower quality-of-life scores than NHW patients with AF. NHW patients receive antiarrhythmic drugs, cardioversions, and invasive therapies more frequently than Black and Hispanic patients. Women have lower rates of AF than men, but experience more severe symptoms, heart failure, stroke, and death after AF diagnosis. Women and people from diverse racial and ethnic backgrounds are inadequately represented in AF trials; prevalence findings may be a result of underdetection.
Conclusion:
Race, ethnicity, and gender are social determinants of health that may impact the prevalence, evolution, and management of AF. This impact reflects differences in biology as well as disparities in treatment and representation in clinical trials.
More Related Videos
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias VII: Nursing Management of Dysrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias V: Evaluating Dysrhythmias

